You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
In the MIMIC-IV v2.2 database the medication files contain dosing information for norepinephrine (NE) in mcg/kg/min. However, it is unclear from the data whether this dosing is reported in equivalent or original dose and for which of the norepinephrine formulation (norepinephrine bitartrate, norepinephrine tartrate, or norepinephrine base). In the prescription table there is some information but it is not really clear.
Request
I would like to request clarification on the type of norepinephrine formulation for which the dosing is reported in the MIMIC-IV database. Understanding this information is crucial for accurate interpretation and analysis of the medication data. This is particularly important now, as the topic of norepinephrine dosing and formulations is being extensively discussed in current articles and literature. At the very least, it would be useful to know which formulation and presentation is usually being used in BIDMC.
Thanks!
The text was updated successfully, but these errors were encountered:
Prerequisites
Description
In the MIMIC-IV v2.2 database the medication files contain dosing information for norepinephrine (NE) in mcg/kg/min. However, it is unclear from the data whether this dosing is reported in equivalent or original dose and for which of the norepinephrine formulation (norepinephrine bitartrate, norepinephrine tartrate, or norepinephrine base). In the prescription table there is some information but it is not really clear.
Request
I would like to request clarification on the type of norepinephrine formulation for which the dosing is reported in the MIMIC-IV database. Understanding this information is crucial for accurate interpretation and analysis of the medication data. This is particularly important now, as the topic of norepinephrine dosing and formulations is being extensively discussed in current articles and literature. At the very least, it would be useful to know which formulation and presentation is usually being used in BIDMC.
Thanks!
The text was updated successfully, but these errors were encountered: